Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Podobne zapisy

• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  od: Nishino, Mizuki, i wsp.
  Wydane: (2016)
• Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
  od: Lo, Peter C., i wsp.
  Wydane: (2015)
• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
  od: Chaft, Jamie E., i wsp.
  Wydane: (2011)
• Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
  od: Mak, Raymond H., i wsp.
  Wydane: (2011)
• New Strategies in Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
  od: Oxnard, Geoffrey R., i wsp.
  Wydane: (2011)